Global Rheumatology Therapeutics Market Industry 2024

1
Rheumatology Therapeutics Market Global Industry
Analysis, Trends, Market Size and Forecasts up to
2024
2
The latest report on Rheumatology
Therapeutics Market by Infinium Global
Research gives complete coverage of the
Rheumatology Therapeutics Market by drug
class (disease modifying anti-rheumatic,
nonsteroidal anti-inflammatory,
corticosteroids, uric acid drugs), disease
indication (rheumatoid arthritis,
osteoarthritis, gout, psoriatic arthritis,
ankylosing spondylitis), distribution channel
(hospital, retail, online pharmacy) in terms of
key trends, market size, forecast and CAGR growth
over the period of 2018 to 2024. In addition,
the study covers deep dive into key
product and applications trends in the
regional markets of Rheumatology Therapeutics
such as North America, Europe, Asia-Pacific and
Latin America over the short run and long
run. The report on global rheumatology
therapeutics market is an in depth analysis
of the segments and sub- segments in the
rheumatology therapeutics market. The report
provides analysis for the global as well
as regional markets over the period of 2016 to
2024. According to report the global rheumatology
therapeutics market is expected to grow at a CAGR
of 2.52 over the forecast period of 2018 -
2024. Market Insight Ardea Biosciences received
approval from FDA for Duzallo (lesinurad and
allopurinol) which help to treatment of
hyperuricemia associated with gout. According
to FDA, Duzallo combination of two
medications with complementary mechanisms of
action with contains lesinurad, a uric acid
reabsorption inhibitor, and allopurinol, a
xanthine oxidase inhibitor. Duzallo lowers
serum uric acid levels by increasing
excretion and inhibiting production of uric
acid. Duzallo is specifically indicated for
the treatment of hyperuricemia associated
with gout in patients who have not
achieved target serum uric acid levels with
a medically appropriate daily dose of
allopurinol alone. Recently, Sanofi and
Regeneron announce FDA approval of Kevzara
(sarilumab) for the treatment of moderately to
severely active rheumatoid arthritis in adult
patients. Kevzara is an interlukin-6 receptor
antibody, which is used for treating adult
patients with moderate to severe stages of active
rheumatoid arthritis (RA) who have shown
indecisive response or intolerance to one or more
3
non-biologic or biologic DMARDs i.e. Disease
Modifying Anti Rheumatic Drugs. The development
of new drugs which help to treat this disease
more effectively called biologics, or disease
modifying agents. The increasing elderly
population worldwide and approval of new drugs
for treating various rheumatic diseases, the
growing awareness among society about the
treatment of rheumatic diseases and
lucrative environment of the treatment has
driven the growth of the market.
Additionally high funding for research and
development activities is likely to boost the
growth of the market. Segments Covered The
report on global rheumatology therapeutics
market covers segments such as drug class,
disease indication, and distribution channel. The
drug class segments include disease modifying
anti-rheumatic drugs, nonsteroidal
anti-inflammatory drugs, corticosteroids, uric
acid drugs and others. On the basis of
disease indication the global rheumatology
therapeutics market is categorized into
rheumatoid arthritis, osteoarthritis, gout,
psoriatic arthritis, ankylosing spondylitis
and others. Furthermore, on the basis of
distribution channel the rheumatology
therapeutics market is segmented as hospital
pharmacy, retail pharmacy and online
pharmacy. Geographic Coverage The report
provides regional analysis covering geographies
such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends
and market size for each geography is provided
over the period of 2016 2024. The
countries covered in the North America
region include the U.S., Canada, and Mexico
while Asia-Pacific includes China, Japan,
India, South Korea and Malaysia among
others. The U.S. drives the growth in the North
America region as it is the largest market in the
region. The Asia-pacific region offers a
substantial potential for the market growth owing
to rapid growth in markets such as India and
China.
4
The APAC region is projected to experience a
healthy growth in terms of CAGR over the period
of 2018 - 2024. Among the regions North America
estimated to be the largest market share on
accounts of prevalence of rheumatic arthritis
in the U.S. and Canada. Growing healthcare
expenditure among the families in the
emerging markets such as China, India among
others coupled with increasing geriatric
population in the region are likely to drive the
growth in the Asia-Pacific region, as a result
the Asia-Pacific rheumatology market is projected
to grow at the swiftest CAGR over the forecast
period. Get a Sample Request https//www.infinium
globalresearch.com/reports/sample_request/1129
Companies Profiled The report provides profiles
of the companies in the global rheumatology
therapeutics market such as, Takeda
Pharmaceutical, Sanofi, Genentech, Inc., Novartis
AG, Janssen Biotech, Inc., Amgen, Inc., AbbVie,
Inc., Pfizer, Inc., Bristol-Myers Squibb Company,
and Merck Co., Inc. Report Highlights The
report provides deep insights on demand
forecasts, market trends and micro and macro
indicators. In addition, this report provides
insights on the factors that are driving and
restraining the Global rheumatology therapeutics
market. Moreover, IGR-Growth Matrix analysis
given in the report brings an insight on
the investment areas that existing or new
market players can consider. The report
provides insights into the market using
analytical tools such as Porters five
forces analysis and DRO analysis of
rheumatology therapeutics market. Moreover, the
study highlights current market trends and
provides forecast from 2018 to 2024. We also have
highlighted future trends in the rheumatology
therapeutics market that will impact the demand
during the forecast period. Moreover, the
competitive analysis given in each regional
market brings an insight on the
5

• market share of the leading players.
  Additionally, the analysis highlights rise and
  fall in the market shares of the key players in
  the market. This report will help the key players
  operating in the rheumatology therapeutics market
  to understand the present and future trends in
  this market and formulate their strategies
  accordingly.
• Make an Enquiry https//www.infiniumglobalresearc
  h.com/reports/enquiry/1129 Table Of Contends
• Preface
• Report Description
• Research Methods
• Research Approaches
• Executive Summar
• Global Rheumatology Therapeutics Market Overview
• Introduction
• Market Dynamics
• 3.2.1 Drivers

3.2.2 Restraints
6

• 3.2.3 Opportunities
• Porters Five Forces Analysis
• IGR Growth Matrix Analysis
• Competitive Landscape in the Global Rheumatology
  Therapeutics Market
• Global Rheumatology Therapeutics Market by Drug
  Class 2018 - 2024
• Disease Modifying Anti-rheumatic Drugs
• Nonsteroidal Anti-inflammatory Drugs
• Corticosteroids
• Uric Acid Drugs
• Others
• Global Rheumatology Therapeutics Market by
  Disease Indication 2018 - 2024
• Rheumatoid Arthritis
• Osteoarthritis
• Gout

5.4 Psoriatic Arthritis Infinium Global Research
7

• Ankylosing Spondylitis
• Others
• Global Rheumatology Therapeutics Market by
  Distribution Channel 2018 - 2024
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Companies Covered
• Takeda Pharmaceutical
• Sanofi
• Genentech, Inc.
• Novartis AG
• Janssen Biotech, Inc.
• Amgen, Inc.
• AbbVie, Inc.
• Pfizer, Inc.

8

• Bristol-Myers Squibb Company
• Merck Co., Inc
• Click the Below Full Report https//www.infiniumg
  lobalresearch.com/healthcare_medical_devices/globa
  l_rheumatology_therapeutics
• _market